UK Markets closed

Centessa Pharmaceuticals plc (CNTA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.20+0.15 (+2.97%)
As of 01:02PM EDT. Market open.
Full screen
Loading interactive chart…
  • Globe Newswire

    Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates

    – Company advances innovative rare disease and immuno-oncology portfolio toward ‘4x24’ goal of four registrational programs in 2024 – – Poster presentation at ASCO 2022 to highlight LB101 preclinical data in solid tumors; IND planned for late 2022 – – ZF874 for AATD Phase 1 update on track for 2H 2022; interim data from multiple dose cohorts with PiMZ and PiZZ subjects – – Cash and cash equivalents of $544.5 million as of March 31, 2022; Operational cash runway to mid-2024 – BOSTON and LONDON, M

  • Globe Newswire

    Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day

    BOSTON and LONDON, March 23, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the Guggenheim Genomic Medicines & Rare Disease Day on Thursday, March 31, 2022, at 11:00 am Eastern Time. Access to the live webcast of this event, as well as archived recordings, will be available under the “Events” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.

  • Globe Newswire

    Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise

    BOSTON and LONDON, March 07, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) (the “Company”), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, today announced that Antoine Yver, MD, MSc, has been appointed Executive Vice President and Chairman of Development. In this newly created role reporting to the CEO, Dr. Yver will be accountable for the Company’s overall develop